Mexoryl SX (Ecamsule) Market Expected to Reach $82.6 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Mexoryl SX (Ecamsule) Market," The mexoryl sx (ecamsule) market was valued at $49.5 million in 2021, and is estimated to reach $82.6 million by 2031, growing at a CAGR of 5.3% from 2022 to 2031.

Mexoryl SX (Ecamsule) is an organic compound that is added to many sunscreens to filter out UVA rays. It possesses excellent photostability, which makes it best-suited for use as an active ingredient in manufacturing anti-ageing creams, long ultraviolet (UVA) ray absorbers, sunscreens, and anti-skin cancer drugs.

The rise in concerns about skin protection against detrimental rays of the sun and improved alertness regarding skin cancer have led the customers become more linear toward using Mexoryl SX (Ecamsule)-based sunscreens. According to a report published by the Indian Ministry of Economy and Industry, the personal care and cosmetics industry is one of the fastest-growing sectors and was worth around $10.5 million in 2021. In addition, incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades where mexoryl SX (ecamsule) is widely used to produce anti-skin cancer drugs. For instance, according to a report published by the World Health Organization (WHO), around 2-3 million cases of non-melanoma skin cancers and 132,000 cases of melanoma skin cancers occur globally each year. This is anticipated to foster the demand for mexoryl (SX) ecamsule market during the forecast period. 

However, lack of awareness among customers about the benefits of mexoryl SX (Ecamsule) may restrain the growth of the mexoryl SX (Ecamsule) market during the forecast period.

On the contrary, rise in R&D activities for developing a broad spectrum of sunscreens formulation where mexoryl SX (ecamsule) is widely used for photo-protection purposes in all skin types may create new opportunities for the market.

The mexoryl (SX) ecamsule market is segmented on the basis of purity level, application, and region. By purity level, the market is segregated into less than 98% and more than 98%. The more than 98% segment dominated the global market in terms of revenue in 2021, with 68.08% of the total share. This is attributed to the increasing incidence of both non-melanoma and melanoma skin cancers. Mexoryl SX (ecamsule) with more than 98% purity levels is widely used to produce anti-skin cancer drugs. This has surged the popularity of mexoryl (SX) ecamsule with more than 98% purity levels among the pharmaceutical sector.

By application, the market is divided into cosmetics, pharmaceuticals, and others. The cosmetics segment dominated the global market in terms of revenue in 2021, with 71.92% of the total share. This is attributed to rising concerns about skin protection against detrimental rays of the sun and improved alertness regarding skin cancer have led the customers become more linear toward using mexoryl SX (ecamsule)-based sunscreens and other cosmetic formulations. This factor may fuel the demand for mexoryl (SX) ecamsule for cosmetics applications.

Region-wise, the mexoryl (SX) ecamsule market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The Europe mexoryl (SX) ecamsule market size is projected to grow at the highest CAGR during the forecast period, owing to increasing proportion of elder population in countries such as Italy and Spain, which in turn has surged the demand for anti-ageing creams where mexoryl SX (ecamsule) acts as an active ingredient in manufacturing various anti-ageing formulations. For instance, according to a report published by Population Reference Bureau, Italy ranks second in world’s oldest populations (aged 65 and above) with 23% of the population with age 65 and above. This factor has augmented the growth of the mexoryl (SX) ecamsule market in the Europe region.

Key players operating in the global mexoryl (SX) ecamsule market include Biosynth Carbosynth, ChemScene LLC, Derma Company, National Analytical Corporation, Norna Technology Co., Skylead Pharmaceuticals & Chemicals, L'Oréal S.A., and MFCI CO., LTD (Hubei Meifeng Chemical Co., Ltd.).

COVID-19 analysis

The novel coronavirus is an incomparable global pandemic that has spread to over 180 countries and caused huge losses of lives and the economy around the globe. The mexoryl SX (ecamsule) market has little impact due to the wake of the COVID-19 pandemic, owing to the disruptions in the supply chain for various personal hygiene, and medical products. Furthermore, to control the surge of novel coronavirus cases, there is a drastic shift of investments from other sectors toward healthcare. Moreover, several ecamsule manufacturing companies have either shut down or shrank their operations due to the risk of infection among the workforce. This has temporarily hampered the demand and supply chain of air-laid products amid the COVID-19 pandemic. However, growth in awareness related to personal care activities has surged the demand for mexoryl SX (ecamsule)-based sunscreens, anti-ageing creams, and other cosmetic products during the COVID-19 pandemic, which in turn has increased the demand for mexoryl SX (ecamsule) market. Furthermore, several ecamsule manufacturing companies have adopted safety strategies and techniques, which in turn may increase the demand for air-laid product as the market starts stabilizing.

In 2020, mexoryl SX (ecamsule) prices were higher in Asia-Pacific. The price rise was, due to continued regional demand trends and tight product availability. Firm downstream air-laid product’s demand and stronger upstream costs are expected to sustain the price gain.

However, the mexoryl SX (ecamsule) market is expected to recover rapidly post COVID-19 situation due to its increased dependency over pharmaceutical other sectors. For instance, according to an article published by Financial Express, the Indian pharmaceutical industry registered a growth of 15% in 2021, and is expected to grow at an average annual growth rate of 18.6% by 2025. This is expected to enhance the performance of the mexoryl SX (ecamsule) post- COVID-19 scenario.

Key findings of the study

• By purity level, the more than 98% segment is estimated to display the highest growth rate, in terms of revenue, registering a CAGR of 5.4% from 2022 to 2031.
• By application, the cosmetics segment is estimated to display the highest growth rate, in terms of revenue, registering a CAGR of 5.4% from 2022 to 2031.
• North America garnered the highest share of 32.93% in 2021, in terms of revenue, growing at a CAGR of 5.2%.